• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed

    1/26/21 8:47:20 AM ET
    $EIDX
    Major Pharmaceuticals
    Health Care
    Get the next $EIDX alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38533
    Issuer: Eidos Therapeutics, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 101 Montgomery Street
    STE 2550
    San Francisco CALIFORNIA 94101
    Telephone number: (917) 922-0730
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-01-26 By O'Neil Blake Senior Specialist
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EIDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EIDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EIDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

      REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

      6/28/21 7:10:00 PM ET
      $IOVA
      $BBIO
      $EIDX
      $BMEA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

      –Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM) –New Drug Application (NDA) for infigratinib for the treatment of cholangiocarcinoma accepted by the U.S. Food and Drug Administration (FDA) under Priority Review designation and Real-Time Oncology Review (RTOR) pilot program, designed to expedite the delivery of safe and effective cancer treatments to patients –Initiated two new clinical trials since las

      2/25/21 7:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

      PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.  The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercialization plans underway for Eidos’ acoramidis, a potential best-in-class therapy for patients with transthyretin (TTR) amyloidosis

      1/26/21 8:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $EIDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: C Jonathan Fox gifted 500 units of Common Stock, decreasing ownership by 100% to 0 units

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:50:50 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Douglas Rohlen

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:39:25 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Franco Valle

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:22:38 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care

    $EIDX
    SEC Filings

    See more
    • SEC Form 15-12B filed

      15-12B - Eidos Therapeutics, Inc. (0001731831) (Filer)

      2/5/21 4:30:52 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed

      EFFECT - Eidos Therapeutics, Inc. (0001731831) (Filer)

      1/28/21 12:15:15 AM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)

      1/26/21 4:10:59 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care

    $EIDX
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

      REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

      6/28/21 7:10:00 PM ET
      $IOVA
      $BBIO
      $EIDX
      $BMEA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

      PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s proposed merger with Eidos and each of the other proposals to be considered at both companies’ virtual special meetings to be held on January 19, 2021.  Under the proposed merger agreement, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right t

      1/4/21 7:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations